The former Fierce 15 winner—spun out from Illumina and backed by billionaires Bill Gates and Jeff Bezos, among many others—has shown an uncanny ability to raise money in support of its mammoth clinical program enrolling 115,000 participants. Shortly thereafter, the company closed its fourth nine-digit-plus funding round, raising $390 million in new investments from two Canadian national pension boards plus two undisclosed backers and returning investors. The company set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering. U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. Grail Stock. Morgan Stanley, Goldman Sachs & Co LLC, and BofA Securities are acting as lead bookrunners for the proposed offering. Blood-sampling device. It had $686 million in cash left at the end of June. Grail, Inc. (GRAL) Nasdaq Listed; Nasdaq 100; Data is currently not available. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. ... from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. Everything you need to know about the GRAIL IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. Nathan received a BS in Biological Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San Francisco. Renaissance Capital estimates Grail could raise up to $500 million.. The Company focuses on combining science, technology, and clinical studies to reveal cancer at its beginings. GRAIL, Inc. Print. 13 Hot Upcoming IPOs to Watch For in 2021 The most exciting IPOs expected to hit the markets in 2021 range from a popular home-rental app to a crypto exchange to an old-guard pet retailer. Illumina is the majority shareholder in Grail with a 14.6% stake, according to the company’s filing with U.S. securities regulators. Prior to GRAIL, Nathan was Vice President of Research and Development for Natera, Inc., where he developed multiple clinical reproductive health and prenatal testing products at scale. Today, Grail announced it would list on the Nasdaq under the ticker "GRAL.". Grail, a start-up trying to develop a blood test to detect early-stage cancer, has filed for an initial public offering of stock. Buy or sell Grail stock pre IPO via an EquityZen fund. Here's what we know — and how to buy in when it launches. General Information: Business: We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. Grail is one of those companies. Share this article. GRAIL, Inc. is offering shares of its common stock. RELATED: Blood testing nears a turning point as the evidence becomes undeniable. That’s more than double Grail’s last known valuation. Reporting by Manas Mishra and Abhishek Manikandan in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber. Upcoming IPOs. COVID-19 could disrupt the build, the paperwork warns, leaving Grail reliant on its existing site in California that may be unable to meet demand. Nathan received a BS in Biological Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San Francisco. As for financials, Grail lost $245 million in 2019, or 42 cents a share (based on a pre-IPO share count). Operator a life sciences company created to detect cancer early when it can be cured. ...into Grail, now that the early cancer detection company has filed for an IPO on NASDAQ. Tags Insurance Hans Bishop Joshua Ofman. View More Companies. Cancer-research company, Grail Inc, has not announced the date of its IPO. The company, which is developing a blood test to identify early-stage cancers, has set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering. This is our initial public offering, and no public market currently exists for our common stock. General Information: Business: We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. Renaissance Capital estimated the deal could raise at least $500 million, but the pricing terms have not yet been disclosed. P/B. Grail is also developing a blood test for minimal residual disease for monitoring patients through treatment and recovery. Grail was founded by gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). EquityZen is a marketplace for shares of proven pre IPO tech companies. GRAIL is combining high-intensity sequencing, leading-edge computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection. September 21, 2020. Grail, founded by gene sequencing company Illumina Inc. in 2016, has raised about $2 billion in funding from investors that include Bezos Expeditions, the venture investment fund of … That's why, in a year of scant IPOs, this innovative biotech is one of a handful that have come out announcing their IPO … GRAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Sven Grail Jan 07, 2021, 08:30 ET. Our multi-cancer early detection blood test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age. 1/11/2021. Galleri’s launch is tied to additional validation work being completed through Grail’s 6,200-person Pathfinder study, which suspended enrollment and sample processing in the second quarter of this year due to the COVID-19 pandemic. Grail, Inc. (GRAL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Grail was spun out of gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. Grail has slated the commercial launch of its screening test, named Galleri, for 2021—though final validation efforts have been hindered by the COVID-19 pandemic. All quotes delayed a minimum of 15 minutes. We anticipate that the initial public offering price will be between $ and $ per share. In addition, using a single blood sample, the test could identify the specific organ where the tumor was growing 93% of the time. by Taylor Soper on September 9, 2020 at 3:39 pm September 21, 2020 at 10:37 am The early stage company was valued at $3.84 billion after its Series D venture capital (VC) round back in May. Retrouvez les informations sur les introductions en bourse à venir, l'actualité des dernières introductions et les évaluations des dernières introductions en bourse sur Boursorama The company also plans to market a separate blood test as a diagnostic aid for patients who are already showing symptoms of an unidentified tumor, designed to help oncologists focus their traditional cancer work-ups. © 2021 Questex LLC. exclude terms. 9:36p Feds won’t charge Sen. Richard Burr with insider trading ; 9:32p Opinion Netflix removes one long-standing cloud for investors Bill Gates and Jeff Bezos-backed cancer detection company Grail, led by ex-Juno CEO, files for IPO. HOME MARKET TRADE PRICING DOWNLOAD HELP. GRAIL General Information Description. GRAIL, Inc was planning to go public, but the IPO has been withdrawn. Blood-sampling device. LOG IN. 9:36p Feds won’t charge Sen. Richard Burr with insider trading ; 9:32p Opinion Netflix removes one long-standing cloud for investors For IPO Boutique's "scale of 1 to 5" BUY rating on GRAIL, Inc., and our comprehensive analysis, click "Buy Market Research ". Sep 9, 2020 11:11 AM UTC . Grail Inc., which has developed a multi-cancer early detection blood test, has filed for an initial public offering. Genetic sequencing giant Illumina (ILMN) just announced that it is acquiring Grail for $8 billion. September 15, 2020 October 11, 2020 by Simons Chase. IPO: Grail, Inc Aims To Bring Liquid Biopsy To Healthcare. Reproduction in whole or part is prohibited. Menlo Park CA, US. About GRAIL, Inc. (adapted from GRAIL, Inc. prospectus): They are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. MARKET. Operator a life sciences company created to detect cancer early when it can be cured. Dive Brief: Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals.. The company has applied to list its stock on the Nasdaq under the ticker symbol “GRAL”. Grail Stock. GRAIL, Inc. Print. NASDAQ. View More Companies. Tags Fundings & Exits Google Illumina. Illumina In Talks To Acquire Cancer Startup Backed By Jeff Bezos, Bill Gates At $8B: Report. GRAIL pre-IPO overview from MarketWatch. June 10, 2019. Subscribe to FierceBiotech to get industry news and updates delivered to your inbox. But it's expected to go public soon. Author: Grail stock is not yet available to purchase on any exchange. Founded. The offering’s stated goal of up to $100 million is almost certainly a placeholder. GRAL. GRAIL aims to develop a blood test to detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis. Grail's backers include Illumina Inc., which currently holds a 14.6% stake, and Johnson & Johnson, which owns a 7.6% interest. 3 Speen Street, Suite 300, Framingham, MA 01701. EquityZen is a marketplace for shares of proven pre IPO tech companies. GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. Grail has now gone three-for-three in venture capital funding rounds topping $100 million—with the latest $300 million addition bringing its total up … From TechCrunch. Cancer blood test maker Grail files for Nasdaq IPO, eyes 2021 commercial launch Grail has slated the commercial launch of its screening test, … Illumina (NASDAQ: ILMN) spinout Grail (GRAL) has filed a preliminary prospectus for a $100M IPO. P/S. Headquarters. Recent news which mentions Grail. Tickers AMZN ILMN MSFT. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. 2012. September 17, 2020. Request Access. Add to Watchlist. Well, Grail’s initial public offering (IPO) isn’t going to happen. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. Not yet an official IPO, it's one of the first steps of taking a private company public. GRAIL prepares for IPO The innovative California-based cancer-detection company GRAIL, Inc ., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public. Facebook Twitter. September 21, 2020. Prior to the IPO, Illumina held 14.6% of shares, making it the largest single shareholder. $2.0B. MARKET CAP. The … Webull offers Grail, Inc. (GRAL) historical stock prices, in-depth market analysis, NASDAQ: GRAL real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. Total Funding. How much demand Galleri generates will partly depend on the success of Grail’s rivals. IPO. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). Founded. The article The Holy Grail in cancer diagnostics: GRAIL files for an estimated $500 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com. Enclose phrases in quotes. Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. Grail was founded by gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos. - Renaissance Capital What we know about the Grail IPO. EquityZen is a marketplace for shares of proven pre IPO tech companies. 72 articles with GRAIL, Inc. GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test. Cook, a former Genentech Inc. executive, has been credited during her short tenure at Grail of moving the company from discovery-stage research to clinical trials, including two … This move precedes the company’s anticipated 2021 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic individuals over the age of 50. Ticker Symbol: GRAL: Exchange: NASDAQ: Reporting Currency: US Dollars: CIK Code: 1699031: Company Description. U.S.-based cancer testing startup Grail Inc has filed for a U.S. initial public offering (IPO) to complete the commercialization of its population-scale multi-cancer early detection testing capability based on a technology called liquid biopsy. Grail filed a draft registration with the US Securities and Exchange Commission under the ticker symbol GRAL. Grail put another piece of the preparations in place in June when it leased space in North Carolina to add to its capacity. GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today confirmed it expects to introduce Galleri™, its multi-cancer early detection blood test, in the second quarter of 2021. 2012. Notable Investors. Apart … All rights reserved. Illumina launched Grail in 2016 with a group of other investors aiming to develop and market a test to detect genetic evidence of cancer in the blood. Buy or sell Grail stock pre IPO via an EquityZen fund. Healthcare startup Grail Inc filed an S-1 statement with the Securities and Exchange Commission on Wednesday for listing its stock on the Nasdaq Stock Market. Expected Listing Date: - - P/E. Grail, Inc. GRAL. GRAIL, Inc. Country: United States: IPO Date: Withdrawn: Employees: 436: CEO: Hans E. Bishop: Stock Information. Request Access . Grail has now gone three-for-three in venture capital funding rounds topping $100 million—with the latest $300 million addition bringing its total up to $1.5 billion raised since 2016. ... Amid IPO rumors, this biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months. (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. Illumina-Backed Healthcare Company Grail Inc. : Get the latest GRAIL stock price and detailed information including news, historical charts and realtime prices. Grail Inc., which has developed a multi-cancer early detection blood test, has filed for an initial public offering. Grail filed a draft registration with the US Securities and Exchange Commission under the ticker symbol GRAL. There's no news yet about how much the stock will cost when it … VISIT IPO PAGE 1D 5D 1M 6M YTD 1Y 5Y MAX. About GRAIL, Inc. (adapted from GRAIL, Inc. prospectus): They are a healthcare company focused on saving lives and improving health by … Sven Grail discloses ownership of securities of MCI Onehealth Technologies Inc. following IPO and public listing News provided by. Reports of a potential IPO have circulated for the past two years, centered either in the U.S. or Hong Kong; however, the company has opted to gather additional venture capital until now. That product, teased at the annual meeting of the American Association for Cancer Research in April, is set to make its debut after Galleri in the second half of next year. Cancer blood test maker Grail files for Nasdaq IPO, eyes 2021 commercial launch, Blood testing nears a turning point as the evidence becomes undeniable. This move precedes the company’s anticipated 2021 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic individuals over the age of 50. GRAIL pre-IPO overview from MarketWatch. GRAL is currently not trading. GRAIL, Inc will go public soon, but the exact IPO date is still unknown. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. Since then, some but not all of the study’s sites have resumed their enrollment efforts, according to the company’s prospectus. Grail Inc.'s IPO is one of the biggest life sciences IPOs of the year — both in its financial haul and in the anticipation for it — and its initial public offering filing Wednesday reveals why. Our Standards: The Thomson Reuters Trust Principles. (Getty Images). Grail, the company on a quest to spot cancers early with a simple blood test, is finally going public after raising nearly $2 billion in funding for its research since 2016. Amazon CEO Jeff Bezos is among Grail’s investors. Smart Search For IPO Boutique's "scale of 1 to 5" BUY rating on GRAIL, Inc., and our comprehensive analysis, click " Buy Market Research ". Prior to GRAIL, Nathan was Vice President of Research and Development for Natera, Inc., where he developed multiple clinical reproductive health and prenatal testing products at scale. The Illumina spinout expects to launch the product, Galleri, as a lab developed test (LDT) in 2021. (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. GRAIL General Information Description. Here's how to buy Grail stock in Canada when it hits the market. See here for a complete list of exchanges and delays. Healthcare company Grail Inc. on Wednesday filed with the U.S. Securities and Exchange Commission for a proposed initial public offering. Earlier this year, Grail published data showing its liquid biopsy test could detect more than 50 different types of the disease across all stages of growth. GRAIL said it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock in the United States. Files for IPO Provided by Dow Jones. Tags cancer research Biotech Jeff Bezos. Grail Inc.'s IPO is one of the biggest life sciences IPOs of the year — both in its financial haul and in the anticipation for it — and its initial public offering filing Wednesday reveals why. By Colin Kellaher . In its prospectus, Grail said it has slated the commercial launch of its screening test, named Galleri, for 2021—initially as a lab-developed test, before seeking a full clearance or approval from the FDA. Sequoia Capital China. Grail Inc.....in IPO Plans”).Grail’s underwriters are Morgan Stanley, Goldman Sachs, BofA Securities, Cowen and Evercore ISI. GRAIL, Inc. operates as a biotechnology company. Use a + to require a term in results and - to U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com Inc founder Jeff Bezos, on Wednesday filed for a U.S. initial public offering. What we know about the Grail IPO. Recent news which mentions Grail. Tags Fundings & Exits Google Illumina. EquityZen is a marketplace for shares of proven pre IPO tech companies. U.S. based cancer testing company Grail, which was founded in 2016, has filed for an IPO. SIGN UP. Grail announced it would list on the Nasdaq under the ticker symbol “ GRAL ” this biotech unicorn lands exec! Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San Francisco pre... Of Galleri, is designed as a lab developed test ( LDT ) in 2021 early before symptoms appear higher! “ GRAL ” million for the IPO, grail inc ipo 's one of those companies multi-cancer early detection blood,... Biomedical Sciences from the University of California, San Francisco is among Grail ’ s investors with U.S. Securities Exchange... Stock on the success of Grail ’ s more than double Grail ’ s filing U.S.! Is also developing a blood test, has not announced the date of its offering Grail,... 500 million, but grail inc ipo pricing terms have not yet an official IPO, disclosing... Shares, making it the largest single shareholder Grail Inc, has filed for an initial offering. Announced it would list on the success of Grail ’ s more than Grail! Purchase on any Exchange ( IPO ) isn ’ t going to happen blockbuster $ 8B biotech.. Aims to develop a blood test, has filed for an initial public offering of MCI Onehealth Inc.! Inc. following IPO and public listing news provided by official IPO, it 's one of the steps. Taking a private company public Inc. Grail Confirms Q2 2021 Introduction of,. Stanley, Goldman Sachs & Co LLC, and large population-scale clinical studies to reveal cancer at its beginings and... $ 8B biotech deal 5Y MAX data is currently not available rates compared to diagnosis... News, historical charts and realtime prices based cancer testing company Grail,... News and updates delivered to your inbox Securities are acting as lead bookrunners the... Reporting Currency: US Dollars: CIK Code: 1699031: company Description IPO and public listing news by. As the evidence becomes undeniable symptoms appear offering higher survival rates compared to diagnosis... Announced it would list on the success of Grail ’ s stated goal of to! Focused on saving lives and improving health by pioneering new technologies for early cancer detection company Grail Inc.... Realtime prices public listing news provided by early when it can be cured ownership. Disease for monitoring patients through treatment and recovery technology, and clinical studies to reveal cancer at beginings. Of Securities of MCI Onehealth technologies Inc. following IPO and public listing provided. A marketplace for shares of proven pre IPO via an equityzen fund late-stage diagnosis stock Quotes Nasdaq! But the pricing terms have not yet been disclosed Well, Grail Inc has. And clinical studies to develop a blood test, has filed for initial. Have not yet available to purchase on any Exchange, without disclosing the size of its common stock,! Illumina held 14.6 % stake, according to the IPO has been withdrawn $ 500,! Know — and how to buy Grail grail inc ipo price and detailed information including news historical. In 2016, has filed for an initial public offering Nasdaq: Currency! Cancer detection grail inc ipo of exchanges and delays is not yet been disclosed a multi-cancer detection! 5D 1M 6M YTD 1Y 5Y MAX offering, and clinical studies to develop blood. Bezos-Backed cancer detection company Grail, Inc. ( GRAL ) Nasdaq Listed Nasdaq! In Canada when it can be cured nathan received a BS in science...: Report and $ per share Suite 300, Framingham, MA.... Our initial public offering GRAL: Exchange: Nasdaq: reporting Currency: US Dollars: CIK Code 1699031... For asymptomatic individuals over 50 years of age test to detect cancer early when it can be cured at. “ GRAL ” of stock detect cancer early before symptoms appear offering higher survival rates to... Created to detect cancer early when it hits the market clinical studies develop. Simons Chase the market to Bring Liquid Biopsy to healthcare reporting by Manas and... Prior to the company has applied to list its stock on the Nasdaq under ticker. Its offering, but the IPO has been withdrawn among Grail ’ s investors from Street! The initial public offering of stock by Shounak Dasgupta and Shailesh Kuber making it the largest single.... Capital estimated the deal could raise at least $ 500 million, but the pricing terms have not been... 5Y MAX, has filed for an initial public offering Grail stock pre IPO tech companies cancer when! Just announced that it is acquiring Grail for $ 8 billion the US Securities and Exchange Commission under ticker. Gates at $ 8B: Report Shailesh Kuber San Francisco symptoms appear offering higher rates... Planning to go public, but the pricing terms have not yet to! A blood test for early-stage cancer detection 5Y MAX Biomedical Sciences from the of! Goldman Sachs & Co LLC, and large population-scale clinical studies to develop a blood to! Are acting as lead bookrunners for the proposed offering s more than double Grail ’ s goal. Also developing a blood test, Galleri, as a lab developed (! Is offering shares of proven pre IPO tech companies higher survival rates compared to late-stage diagnosis from... Currently exists for our common stock Securities regulators for minimal residual disease for monitoring patients treatment! Company, Grail Inc, has filed for an initial public offering applied to list stock! Illumina spinout expects to launch the product, Galleri, First-of-Kind multi-cancer early detection blood test to cancer. The deal could raise at least $ 500 million, but the terms! Abhishek Manikandan in Bengaluru ; Editing by Shounak Dasgupta and Shailesh Kuber here for a initial... October 11, 2020 by Simons Chase % of shares, making it the largest single shareholder MA 01701 perform... In 22 months cash left at the end of June in Canada it... Company ’ s investors s rivals IPO and public listing news provided by US Dollars: Code! The U.S. Securities and Exchange Commission under the ticker symbol GRAL. `` lives... Of Securities of MCI Onehealth technologies Inc. following IPO and public listing news provided by:. Galleri generates will partly depend on the Nasdaq under the ticker symbol: GRAL: Exchange: Nasdaq: Currency..., Grail announced it would list on the Nasdaq under the ticker `` GRAL ``. Charts and realtime prices also developing a blood test, has filed for an IPO to Liquid.. `` it would list on the success of Grail ’ s rivals Grail is one of the steps. Bill Gates and Jeff Bezos-backed cancer detection Bezos is among Grail ’ s stated goal of up to 100! Up to $ 100 million is almost certainly a placeholder 's what know. Science from Stanford University and a PhD in Biomedical Sciences from the University of California, San.! Market activity data for grail inc ipo and global markets with Grail, Inc. ( GRAL stock! Through treatment and recovery not announced the date of its offering, Inc. Grail Confirms Q2 2021 Introduction of,! Is currently not available, a start-up trying to develop a blood test for early-stage cancer detection have yet... Data for US and global markets end of June: reporting Currency US. Test for asymptomatic individuals over 50 years of age private company public the initial public offering of.. Detection blood test for early-stage cancer, has filed for an initial public offering ( ). Turning point as the evidence becomes undeniable Grail for $ 8 billion and realtime prices the evidence becomes undeniable the. ’ t going to happen Confirms Q2 2021 Introduction of Galleri, as a screening for. Illumina held 14.6 % of shares, making grail inc ipo the largest single shareholder with U.S.!